Galway-based medical device and drug delivery company Aerogen has announced that it is creating thirteen new high-tech positions at its base in Dangan.
The new recruits will join the company’s fast-growing team of more than 60 science, business and engineering graduates, many educated to PhD level, with the workforce expected to hit 80 by the end of the year.
The new positions cover a wide range of disciplines including Engineering, Biomedical Engineering, Mechanical Design and IT.
The rapid expansion follows a landmark homecare product and technology deal with Philips in January, which will see Aerogen focus on its core area of respiratory drug delivery in acute care and homecare ventilation settings.
The announcements cap off an outstanding year for the company which was awarded the prestigious Zenith Award from the American Association of Respiratory Care (AARC) in November and named Medical Technology Company of the Year Award by the Irish Medical Device Association (IMDA) in December.
John Power, CEO, Aerogen said: “The company has ambitious plans for the next few years as we focus on expanding our core business in the acute care setting, whilst facilitating consistency of care for respiratory patients from hospital to home. We are constantly on the lookout for exceptionally talented and motivated people to join our ever expanding team. The immediate recruitment plans are to fill 13 new positions in Galway to support the expansion of our leadership position across all areas of aerosol drug delivery in the hospital environment.”
Founded in Galway in 1997 as Cerus Medical, Aerogen has grown to become the global leader in acute care aerosol drug delivery equipment. Today its Aeroneb® products play a critical role in treating patients on life-support ventilation in over 65 countries worldwide.
Since spearheading a $10 million management buy-out in December 2007, CEO John Power has led Aerogen to become one of the fastest growing companies in the field of medical technology achieving over 30 per cent year-on-year revenue growth.